ABL DiagnosticsXPAR:ABLD +0.80%50 Return-on-Tangible-Equity is 31.48% as of Dec. 2025, which is 733% above its 10-year median of 3.78. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.77 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 579 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 69.43% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ABL Diagnostics's annualized net income for the quarter that ended in Dec. 2025 was €1.40 Mil. ABL Diagnostics's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €4.44 Mil. Therefore, ABL Diagnostics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 31.48%.
The historical rank and industry rank for ABL Diagnostics's Return-on-Tangible-Equity or its related term are showing as below:
XPAR:ABLD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -7.58 Med: 3.78 Max: 31.29
Current: 21.69
During the past 13 years, ABL Diagnostics's highest Return-on-Tangible-Equity was 31.29%. The lowest was -7.58%. And the median was 3.78%.
XPAR:ABLD's Return-on-Tangible-Equity is ranked better than 69.43% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs XPAR:ABLD: 21.69
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ABL Diagnostics Return-on-Tangible-Equity Related Terms
ABL Diagnostics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, ABL Diagnostics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 31.48% mean?
ABL Diagnostics (XPAR:ABLD) has a Return-on-Tangible-Equity of 31.48% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ABL Diagnostics and its competitors. This is 733% above median its historical median of 3.78. According to the industry distribution chart, ABL Diagnostics ranks #177 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 30.6%.
Is ABL Diagnostics' Return-on-Tangible-Equity too high?
ABL Diagnostics' current Return-on-Tangible-Equity of 31.48% is 733% above median its 10-year median of 3.78. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. ABL Diagnostics' value of 31.48% is 208.3% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #177 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #177 out of 579 companies for Return-on-Tangible-Equity. This puts ABL Diagnostics in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.21. ABL Diagnostics' value of 31.48% is 208.3% above this benchmark. While the company's 10-year median is 3.78 vs. the industry median of 10.21, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Return-on-Tangible-Equity of 31.48% is 208.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Return-on-Tangible-Equity is 31.48%, which is 733% above median its own 10-year median of 3.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.77, compared to a current price of €2.52 — trading 67.6% below its estimated fair value. The current Return-on-Tangible-Equity is 31.48%, which is 733% above median its 10-year median of 3.78 and 208.3% above the Healthcare Providers & Services industry median of 10.21. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Return-on-Tangible-Equity is 31.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.52 is trading 67.6% below its estimated GF Value™ of €7.77.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Return-on-Tangible-Equity: 31.48% (733% above median its 10-year median of 3.78)
GF Value™: €7.77 vs. price of €2.52 (67.6% below fair value)
Industry Position: 208.3% above the Healthcare Providers & Services median (#177 of 579)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
